Nektar Therapeutics sell nabucco
Start price
17.03.20
/
50%
€13.38
Target price
04.11.21
-
Performance (%)
17.79%
End price
21.04.21
€15.76
Summary
This prediction ended on 21.04.21 with a price of €15.76. The prediction closed with a disappointing performance of 17.79%. nabucco has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Nektar Therapeutics | 6.761% | 6.761% | 70.977% | -91.776% |
iShares Core DAX® | 1.195% | 2.111% | 17.166% | 16.919% |
iShares Nasdaq 100 | 3.220% | -1.375% | 22.801% | 33.740% |
iShares Nikkei 225® | 1.858% | 0.888% | 10.064% | -0.682% |
iShares S&P 500 | 2.168% | 0.612% | 22.739% | 38.274% |
Comments by nabucco for this prediction
In the thread Nektar Therapeutics diskutieren
Sell Nektar Therapeutics